Cost-effectiveness of prize-based incentives for stimulant abusers in outpatient psychosocial treatment programs

• Published in: Drug and alcohol dependence 2007-03, Vol.87 (2), p.175-182
• Main Authors: Olmstead, Todd A, Sindelar, Jody L, Petry, Nancy M
• Format: Article
• Language: English
• Subjects: Addictive behaviors; Adult and adolescent clinical studies; Biological and medical sciences; Contingency management; Cost effectiveness; Cost-Benefit Analysis; Costs and Cost Analysis; Counseling; Drug abuse; Drug addiction; Family; Female; Humans; Incentives; Male; Medical sciences; MIEDAR; Motivational incentives; Narcotic Antagonists - therapeutic use; Outpatients; Patient Acceptance of Health Care; Psychiatry; Psychological Tests; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Reward; Social Support; Stimulant abuse; Stimulants; Substance abuse treatment; Substance-Related Disorders - economics; Substance-Related Disorders - psychology; Substance-Related Disorders - rehabilitation; Toxicology; Treatment methods; Treatment Outcome
• ISSN: 0376-8716; 1879-0046
• DOI: 10.1016/j.drugalcdep.2006.08.012

Abstract Objective To evaluate the cost-effectiveness of a prize-based intervention as an addition to usual care for stimulant abusers. Methods This cost-effectiveness analysis is based on a randomized clinical trial implemented within the National Drug Abuse Treatment Clinical Trials Network. The trial was conducted at eight community-based outpatient psychosocial drug abuse treatment clinics. Four hundred and fifteen stimulant abusers were assigned to usual care ( N = 206) or usual care plus abstinence-based incentives ( N = 209) for 12 weeks. Participants randomized to the incentive condition earned the chance to draw for prizes for submitting substance negative samples; the number of draws earned increased with continuous abstinence time. Incremental cost-effectiveness ratios were estimated to compare prize-based incentives relative to usual care. The primary patient outcome was longest duration of confirmed stimulant abstinence (LDA). Unit costs were obtained via surveys administered at the eight participating clinics. Resource utilizations and patient outcomes were obtained from the clinical trial. Acceptability curves are presented to illustrate the uncertainty due to the sample and to provide policy relevant information. Results The incremental cost to lengthen the LDA by 1 week was US$ 258 (95% confidence interval, US$ 191–401). Sensitivity analyses on several key parameters show that this value ranges from US$ 163 to 269. Conclusions Compared with the usual care group, the incentive group had significantly longer LDAs and significantly higher costs.